ArticleComputational and structural biotechnology journal2025
ExoOrb: A novel visual and analytical system for therapeutic extracellular vesicles metrics.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are naturally secreted nanoscale mediators of intercellular communication, showing potential for therapeutic and functional food applications. Although many EVs are being isolated with claims of therapeutic benefits, the evaluation criteria require extensive resources and time, often resulting in futile outcomes. This work addresses this gap by developing a visual and quantitative system using monk fruit cell-derived EVs (MFEVs) as a model to efficiently select the most suitable therapeutic EVs by analyzing their characterization parameters. This approach saves valuable resources and time. To generate variations, MFEVs were isolated using eight different techniques: ultracentrifugation, ultrafiltration, polyethylene glycol (PEG) precipitation (8 %, 10 %, 15 %, and 20 %), anion-exchange chromatography, and a novel combined ultrafiltration-precipitation method. Following isolation, their physicochemical properties, biochemical composition, and bioactivity were characterized, and their dose-dependent anticancer effects were evaluated across multiple cancer cell lines. Next, using data from the correlative statistics of anticancer activity with characterization parameters, "ExoOrb" is developed. It is an analytical multicriteria decision-making system that objectively ranks the therapeutic potential of EVs by employing factor normalization, weighted scoring, and multidimensional visualizations. The system has been validated using both the original dataset and synthetic datasets. The original dataset identified PEG 10 %-MFEVs as more effective therapeutically, and the synthetic dataset confirmed ExoOrb's ability for metrisizing EVs across multiple EVs types. To our knowledge, ExoOrb is the first potentially universal framework for evaluating the therapeutic potential of EVs based on characterization parameters, providing a reliable tool for scientific and therapeutic research through standardized, data-driven optimization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.